This Round Table Discussion reviews NOACs in secondary stroke prevention.
Following completion of this activity, learners will be able to:
- Recall key scientific data of the NOAC trials in SPAF incl. secondary stroke prevention
- Outline key clinical questions when starting patients on NOACs, incl. potential need for reversal
- Select an appropriate NOAC for their AF patients based on these considerations
Robin Lemmens – MD, PhD, Department of Neurosciences, Experimental Neurology, Leuven Research Institute for Neuroscience and Disease, KU Leuven – University of Leuven, Leuven, Belgium
Milan Voško – MD, PhD, Department of Neurology, Kepler Universitätsklinikum, Linz, Austria
Ales Tomek – MD, PhD, FESO, Neurology Department, 2nd Medical Faculty of Charles University, Prague, Czech Republic